Transcriptome sequencing and survival analysis of noncirrhotic hepatitis B viral（HBV）-related hepatocellular carcinoma

doi:10.3969/j.issn.1006-7795.2023.05.016

Abstract

Abstract: Objective Transcriptome sequencing and bioinformatics analysis were used to explore the transcriptional characteristics and survival analysis of non-cirrhotic hepatitis B viral（HBV）-related hepatocellular carcinoma (HCC). Methods The differentially expressed genes in non-cirrhotic HBV-related HCC were obtained by transcriptome sequencing. The biological functional processes and signaling pathways involved in the differentially expressed genes were obtained by gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis. The key genes were obtained by gene-gene function interaction network analysis, and the key genes were analyzed for survival prognosis using the cancer genome atlas (TCGA) database’s HCC cohort. Results A total of 3 672 up-regulated differential genes and 2 715 down-regulated differential genes were identified. The GO functional enrichment analysis mainly involved cell differentiation, DNA replication, DNA repair, inflammation response, immune response, cell adhesion, etc, while the KEGG pathway enrichment mainly included cell cycle, oxidative phosphorylation, p53 signaling pathway,tumor necrosis factor（TNF） signaling pathway, and nuclear factor kappa-B（NF-κB） signaling pathway. Among them, high expression of mitogen-activated protein kinase 3（MAPK3）, ras-related C3 cotulinum toxin substrate 1（RAC1）,phospholipase C beta 1（PLCβ1）, catenin beta 1（CTNNβ1）, non-metastatic cells 1（NME1）, and non-metastatic cells 6（NME6） was associated with poor prognosis in HCC patients (P<0.05), while low expression of FYN, cytochrome P450 2C8（CYP2C8）, and cytochrome P450 2C9（CYP2C9） was associated with poor prognosis in HCC patients (P<0.05). Conclusions Non-cirrhotic HBV-related HCC involves multiple biological processes and alterations in signaling pathways, and the key genes related to the survival and prognosis of HCC patients provide new clues for understanding the mechanism of HBV-related HCC in non-cirrhosis patients.

Key words: non-cirrhotic hepatocellular carcinoma, differentially expressed genes, signalling pathways

CLC Number:

Wan Yan, Liu Fang, Guo Shan, Wu Jian. Transcriptome sequencing and survival analysis of noncirrhotic hepatitis B viral（HBV）-related hepatocellular carcinoma[J]. Journal of Capital Medical University, 2023, 44(5): 811-820.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2023.05.016

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2023/V44/I5/811

References

［1］Kelley R K, Greten T F. Hepatocellular carcinoma-origins and outcomes［J］. N Engl J Med, 2021, 385(3): 280-282.
［2］Desai A, Sandhu S, Lai J P, et al. Hepatocellular carcinoma in non-cirrhotic liver: a comprehensive review［J］. World J Hepatol, 2019, 11(1): 1-18.
［3］Cucchetti A, Zhong J H, Berhane S, et al. The chances of hepatic resection curing hepatocellular carcinoma［J］. J Hepatol, 2020, 72(4): 711-717.
［4］Skidmore Z L, Kunisaki J, Lin Y, et al. Genomic and transcriptomic somatic alterations of hepatocellular carcinoma in non-cirrhotic livers［J］. Cancer Genet, 2022, 264/265: 90-99.
［5］Hyuna S, Jacques F, Rebecca L S, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］. CA Cancer J Clin, 2021, 71(3): 209-249.
［6］Yang Y Q, Wen Z Y, Liu X Y, et al. Current status and prospect of treatments for recurrent hepatocellular carcinoma［J］. World J Hepatol, 2023, 15(2): 129-150.
［7］Levrero M, Zucman-Rossi J. Mechanisms of HBV-induced hepatocellular carcinoma［J］. J Hepatol, 2016, 64(1 Suppl): S84-S101.
［8］Farazi P A, DePinho R A. Hepatocellular carcinoma pathogenesis: from genes to environment［J］. Nat Rev Cancer, 2006, 6(9): 674-687.
［9］Moon H, Ro S W. MAPK/ERK signaling pathway in hepatocellular carcinoma［J］. Cancers (Basel), 2021, 13(12): 3026.
［10］Sauzeau V, Beignet J, Vergoten G, et al. Overexpressed or hyperactivated Rac1 as a target to treat hepatocellular carcinoma［J］. Pharmacol Res, 2022, 179: 106220.
［11］Liang S H, Guo H R, Ma K, et al. A PLCβ1-PI3K-AKT signaling axis activates EMT to promote cholangiocarcinoma progression［J］. Cancer Res, 2021, 81(23): 5889-5903.
［12］Javanmard D, Najafi M, Babaei M R, et al. Investigation of CTNNβ1 gene mutations and expression in hepatocellular carcinoma and cirrhosis in association with hepatitis B virus infection［J］. Infect Agent Cancer, 2020, 15: 37.
［13］Yang J, Lv Z H, Huang J T, et al. High expression of NME1 correlates with progression and poor prognosis in patients of hepatocellular carcinoma［J］. Int J Clin Exp Pathol, 2017, 10(8): 8561-8568.
［14］Proust B, Radi M, Vidac∨ek N , et al. NME6 is a phosphotransfer-inactive, monomeric NME/NDPK family member and functions in complexes at the interface of mitochondrial inner membrane and matrix［J］. Cell Biosci, 2021, 11(1): 195.
［15］Huang C K, Zhou J J, Nie Y, et al. A new finding in the key prognosis-related proto-oncogene FYN in hepatocellular carcinoma based on the WGCNA hub-gene screening trategy［J］. BMC Cancer, 2022, 22(1): 380.
［16］Wang X K, Yu T D, Liao X W, et al. The prognostic value of CYP2C subfamily genes in hepatocellular carcinoma［J］. Cancer Med, 2018, 7(4): 966-980.

[1]	Xiao Zeru, Yan Rui, Liang Ziwei, Ge Yang, An Guangyu. Major tobacco carcinogen benzo(a)pyrene induces infiltration of M2 type macrophages by upregulating cyclooxygenase-2 expression in esophageal squamous carcinoma [J]. Journal of Capital Medical University, 0, (): 753-761.
[2]	Tan Yubo, Suboyinuer Tuerhong, Huang Jing, Zhang Tingting, Liu Junjie, Shaya Mahati. The mechanism of miR-150 targeted regulation of IGF2BP2 on the malignant phenotype of liver cancer [J]. Journal of Capital Medical University, 2023, 44(5): 762-767.
[3]	Yu Jianyu, Zheng Yi, Li Wenbin. Bioinformatics analysis of hippocalcin like 1 expression and clinical prognosis in primary central nervous system lymphoma [J]. Journal of Capital Medical University, 2023, 44(5): 724-732.
[4]	Zheng Yi, Song Lairong, Xu Xiaoying, Wu Zhen, Li Xiaojie, Xie Lei, Chen Feng, Li Wenbin. Construction and application of the human glioblastoma cell line Y1203 [J]. Journal of Capital Medical University, 2023, 44(5): 733-740.
[5]	Liu Xiu, Li Wencai. Preliminary study on the effect of UNC0379 on the proliferation of glioma cells [J]. Journal of Capital Medical University, 2023, 44(5): 741-746.
[6]	Peng Yichen, Zheng Yi, Li Shenglan, Yu Jianyu, Lan Yanjie, Liu Xinrui, Chen Feng, Li Wenbin. Study of genes associated with aberrant methylation regulation in high-grade meningiomas [J]. Journal of Capital Medical University, 2023, 44(5): 747-752.
[7]	Yin Xue, Yu Minghang, Wang Xi, Chen Jinglong. Progresses on the mutation of SWI/SNF complex and its impact on immune checkpoint inhibitor therapy response in hepatocellular carcinoma [J]. Journal of Capital Medical University, 2023, 44(5): 768-774.
[8]	Yin Shuo, Chen Feng, Zheng Xiaohong, Zhang Weichunbai, Li Wenbin. Novel drug therapies promote the treatment progress of primary central nervous system lymphoma [J]. Journal of Capital Medical University, 2023, 44(5): 775-781.
[9]	Xu Jingxing, Zhou Quan, Ying Jianming. Recent progress on immunotherapy for tumor microenvironment of triple negative breast cancer [J]. Journal of Capital Medical University, 2023, 44(5): 882-888.
[10]	Ning Tingting, Wang Zhaoqing, Zhang Nan, Zhu Shengtao. Clinical importance of ACE2 expression in colon cancer and susceptibility of colon cancer cells to three human coronaviruses using ACE2 as their receptor [J]. Journal of Capital Medical University, 2023, 44(4): 663-668.
[11]	. Oncologic and functional outcomes after laparoscopic radical prostatectomy:10-years follow-up [J]. Journal of Capital Medical University, 2023, 44(3): 424-432.
[12]	Zhu Guangyi, Wang Runjin, Xiong Tianyu, Ye Xiaobo, Liu Zhanliang, Cao Fang, Lin Zhemin, Niu Yinong. Analysis of risk factors for second primary malignancies after radical prostatectomy for non-metastatic prostate cancer [J]. Journal of Capital Medical University, 2023, 44(3): 433-438.
[13]	Wang Runjin, Ye Xiaobo, Zhang Yudong, Zhu Guangyi, Yang Kun, Niu Yinong. Effect of different invasion patterns on the prognosis of patients with T3a renal cell carcinoma [J]. Journal of Capital Medical University, 2023, 44(3): 439-448.
[14]	Zhang Yudong, Wei Houyi, Wang Runjin, Jiang Mingxin, Yang Kun, Wang Mingshuai, Wasilijiang Wahafu, Song Liming, Jin Mulan, Xing Nianzeng, Niu Yinong. Prognostic significance of the controlling nutritional status (CONUT) score in patients with bladder cancer treated with radical cystectomy and ileal conduit [J]. Journal of Capital Medical University, 2023, 44(3): 449-456.
[15]	Xiong Tianyu, Niu Yinong. Mechanism of periprostatic adipose tissue affecting the development of prostate cancer [J]. Journal of Capital Medical University, 2023, 44(3): 457-462.